An observational study in Myocardial Ischemia, sponsored by IHF GmbH - Institut für Herzinfarktforschung. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by IHF GmbH - Institut für Herzinfarktforschung · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Myocardial Ischemia with a site in Germany — 5 open to participants now, 12 under way, none of them phase 3. Myocardial Ischemia · Germany.
Among the 62 studies in Myocardial Ischemia with a site in Germany, this one is the 3rd largest by enrollment of the 18 observational ones that give a count, is one of 2 that started in 2023, is one of 18 observational ones, and was the 55th registered.
1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.
Browse Myocardial Ischemia studies →5 of the 62 studies in Myocardial Ischemia with a site in Germany are open now. Recruiting first, the newest first:
Zoll Medical Corporation · Sites in Germany
Ages 18+
University Hospital, Essen · Sites in Germany
Ages 18+
iATROS GmbH · Sites in Germany
Ages 18+
Philips Clinical & Medical Affairs Global · Sites in Germany, United States, Australia and 15 more countries
Ages 18+
Heinrich-Heine University, Duesseldorf · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 11 · Phase 4 7
First in 2002; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,684 is above the median of 318 across 398 observational studies indexed under Myocardial Ischemia.
Median enrollment 401 across the 43 interventional studies, 599 across the 18 observational. Of the 36 that completed or were terminated, 10 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 62 have an industry lead sponsor. The 10 most frequent:
IHF GmbH - Institut für Herzinfarktforschung is the lead sponsor of 16 studies on the registry; 4 are open to participants now.
IHF GmbH - Institut für Herzinfarktforschung has 1 study filed under Myocardial Ischemia — fewer than ten, so there is no comparison to draw.
3 of the studies in Myocardial Ischemia with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05540223Biotronik AGSafety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System | 2027-02 |
| NCT06678490OrbusNeichSupport C Post-Market Registry | 2027-02 |
| NCT07091682Biotronik AGSafety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 62 studies in Myocardial Ischemia with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims to assess contemporary practice in OCT use during routine interven-tional practice and to assess the impact of the MLD-MAX algorithm on real-world PCI in a large unselected European all-comer-study cohort.
Angiography is the current standard method to guide PCI strategy in clinical practice. However, angiography has a number of well-described limitations, primarily through only providing an assessment of luminal dimensions without delineation of the burden of atheroma-tous disease. Angiography also provides suboptimal assessment of post PCI complications such as stent underexpansion or malapposi-tion, residual dissections or thrombus, and tissue prolapse. These limi-tations may be overcome in part by intravascular imaging (IVI), which allows tomographic, cross-sectional imaging of the vessel wall. Meta-analyses of randomized and registry studies of IVI-guided vs. angi-ography-guided PCI have suggested that IVI-guidance may improve clinical outcome following PCI.
Optical coherence tomography (OCT) provides high-resolution (10-20 μm) cross-sectional images of plaque microarchitecture, stent place-ment and size and strut coverage. Recently the MLD-MAX algorithm was developed to guide and stand-ardize coronary stent implantation based on sizing of the vessel at the proximal and distal reference using the EEL.
Patients with evidence of myocardial ischemia (e.g. stable angina, silent ischemia, unstable angina, or acute myocardial infarction) un-dergoing OCT-guided lesion evaluation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No study arms; one patient population will be observed.
Other: No intervention planned
No intervention planned; study is observational
Stent expansion: number of participants with optimal / acceptable / unacceptable stent expansion
Stent expansion is defined by the MSA achieved in the proximal and distal stented segments relative to their respective reference lumen areas. Stent expansion will be categorised as follows: Optimal stent expansion (y/n); acceptable stent expansion (y/n); unacceptable stent expansion (y/n); post-PCI stent expansion (%).
Time frame: At baseline
Minimal Stent Area (MSA)
Imaging Outcome: minimal stent area as continuous measure; Final Post-PCI MSA (per target lesion basis) assessed by final-OCT after PCI; measured at an independent OCT core laboratory. Imaging-Outcome: Minimal-Stent-Area (MSA), continuous measure
Time frame: At baseline
Mean stent expansion
The mean stent area (stent volume/analyzed stent length) divided by the average of proximal and distal reference lumen areas x 100
Time frame: At baseline
Intra-stent plaque protrusion and thrombus: number of major and minor protusion area / stent area
Defined as a mass attached to the luminal surface or floating within the lumen, meeting the following criteria: Protrusion/thrombus is defined as any intraluminal mass protruding at least 0.2 mm within the luminal edge of a stent strut, and will be further classified as Major and Minor: * Major: Protrusion area/Stent area at site of tissue protrusion ≥10% and the minimal intra-stent flow area (MSA - protrusion area) is unacceptable (\<90% of respective proximal or distal reference area * Minor: Protrusion area/Stent area at site of tissue protrusion is \<10%, or is ≥10% but the minimal intraluminal flow area (MSA - protrusion area) is acceptable (≥90% of respective proximal or distal reference area
Time frame: At baseline
Number of participants with untreated reference segmant disease
Defined as focal disease with untreated MLA \<4.5 mm2 within 5 mm from the proximal and/or distal stent edges. Sub-classified by the amount of untreated lipid plaque, divided into 3 grades: Low (≤90° of lipid arc), Medium (\>90°-\<180° of lipid arc) and High (≥180° of lipid arc).
Time frame: At baseline
Number of participants with major and minor edge dissections
Edge dissections will be tabulated as: * Major (%): ≥60 degrees of the circumference of the vessel at site of dissection and ≥3 mm in length * Minor (%): any visible edge dissection \<60 degrees of the cir-cumference of the vessel or \<3 mm in length
Time frame: At baseline
Number of participants with major and minor stent malapposition
Defined as frequency (%) of incompletely apposed stent struts (defined as stent struts clearly separated from the vessel wall (lumen bor-der/plaque surface) without any tissue behind the struts with a distance from the adjacent intima of ≥0.2 mm and not associated with any side branch). Malapposition will be further classified as: * Major: if associated with unacceptable stent expansion (as de-fined above) * Minor: if associated with acceptable stent expansion (as defined above) Stent Malapposition will be tabulated as: Major (%); Minor (%); All (Major and Minor) (%)
Time frame: At baseline
Number of participants with procedural complications
Defined as prolonged ST-segment elevation or depression (\>30 minutes), cardiac arrest or need for defibrillation or cardioversion or hypotension/heart failure requiring mechanical or intravenous hemody-namic support or intubation or procedural death
Time frame: At baseline
Number of participants with adverse events
Target lesion failure (TLF; cardiac death, TV-MI or ischemia-driven target lesion revascularization)
Time frame: At 30 days follow-up
Number of participants with adverse events
Target lesion failure (TLF; cardiac death, TV-MI or ischemia-driven target lesion revascularization)
Time frame: At 6 months follow-up
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2023 to primary completion in Mar 2026, 33 months.
Of 165 non-industry observational studies under Myocardial Ischemia, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 127. This study's 33 months is below that.
Counting every sponsor, half of 204 studies reached it within 40 months; a quarter within 21 and three quarters within 90.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Apr 2026 → Mar 2026 and completion Apr 2026 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IHF GmbH - Institut für Herzinfarktforschung